跳至主要内容
临床试验/EUCTR2007-000503-15-IT
EUCTR2007-000503-15-IT进行中(未招募)不适用

Experimental clinical open study, randomized, experimental group vs control group, for the evaluation of tolerability and the effects on magnetic resonance parameters and cognitive functions of memantine in patients at early stage of relapsing- remitting multiple sclerosis treated with interferon-beta. - NEMESI-MS Neuroprotection by Memantine at Early Stage In Multiple Sclerosis

AZ. OSPEDALIERA GARIBALDI, S.LUIGI CURRO , ASCOLI TOMASELLI0 个研究点开始时间: 2007年4月20日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Onset of IFN-beta treatment within 3 months Diagnosis of clinically defined Multiple Sclerosis within 2 years according to McDonald s criteria Aged between 18 and 50 years EDSS 8804;3.5 Free from corticosteroids since at least 60 days, from immunosuppressors since at least 6 months and free of other immunomodulators since at least 2 months prior to enrollmentPatients willing to sign informed consent Patients with Beck Depression score 8804;10
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Pregnant, breast-feeding women or those planning pregnancy Primary or secondary epilepsy Serious psychiatric pathologies Alcohol or drug abuse Serious systemic diseases with particular reference to endocrinopathies and metabolic diseases Brain trauma with sequels Depression evaluated according to Beck s scale score 10 Serious impairment and disablement that can interfere with performance of tests

研究者

发起方
AZ. OSPEDALIERA GARIBALDI, S.LUIGI CURRO , ASCOLI TOMASELLI

相似试验